Part A. PERSONAL INFORMATION

CV date	16/06/2022

First and Family name	Guillermo Velasco Díez		
Social Security, Passport, ID number	50443341V	Age	52
Researcher numbers	Researcher ID	H-5260-2012	
	Author ID	"Velasco, Guillermo" 7006478965	
	ORCID code	0000-0002-1994-2386	

A.1. Current position

Name of University/Institution	Universidad Complutense de Madrid and Instituto de Investigación Sanitaria del Hospital Clínico San Carlos		
Department	Bioquímica y Biología Molecular		
Address and Country	Fac. Biología Edif B, Calle José Antonio Nováis 12, 28040-Madrid		
Phone number	913945034	E-mail	gvelasco@ucm.es
Current position	Associate Professor (Profesor Titular de Universidad y jefe de grupo del IdISSC (ONC.5)	From	02/02/2008
UNESCO code			
Key words	Cell signaling, Autophagy, Cancer, Cannabinoids, Sphingolipids,		

A.2. Education

Degree/PhD	University	Year
BsC and MSc in Biology	Universidad Complutense de Madrid	1993
PhD Biology	Universidad Complutense de Madrid	1997

A.3. JCR articles, h Index, thesis supervised…

Number of 6 years research periods "sexenios de Investigación": 4 (1994-1999; 2000-2005; 2006-2011; 2012-2017). Date of the last "sexenio" granted: 2018. 1 transference sexenio (2009-2014) Date of granting 2020

Number of PhD thesis supervised: 6 (5 in the last 10 years) (+ 4 under development)

Total citations (WoS): 14.619 (years: number of citations): 2021 > 2500; 2020 > 1600; 2019 > 1400; 2018: >1400; 2017: >1400; 2016 >1200; 2015: >900); **h index (WoS): 47**; h-index (Google scholar): 54; h index (scopus): 46. Total JCR publications: 99; First decile publications (D1): 31; First quartile publications (Q1 - D1): 45; Publications as "corresponding/senior author": 32

Part B. CV SUMMARY *(max. 3500 characters, including spaces)*

Guillermo studied Biology (1988-1993) and carried out his doctoral thesis in the Department of Biochemistry and Molecular Biology I of the Faculty of Chemical Sciences of the Complutense University under the direction of Dr. Manuel Guzmán (1994-1997) in the topic: Mechanisms of regulation of fatty acid oxidation in rat liver). Later he made a post-doctoral stay in the laboratory of Dr. Philip Cohen (1998-1999) at the University of Dundee, Scotland where he studied the role of Rho Kinase in the regulation of smooth muscle contraction and became familiar with molecular biology techniques and the study. of cell signaling mechanisms.

In 1999 he rejoined the Department of Biochemistry and Molecular Biology I as Assistant Professor, later obtaining a position as "Professor Contratado Doctor" (2003). Since February 2008, Guillermo Velasco is Associate Professor ("Profesor Titular de Universidad") of the Department of Biochemistry and Molecular Biology I of the Complutense University of Madrid. Starting in 2001 and within the Cannabinoid Signaling Group, Guillermo Velasco has been developing a line of research focused on the study of the molecular mechanisms underlying the anti-tumor action of cannabinoids, as well as on the optimization of the conditions of use of these agents for their possible clinical application.

The results of the studies developed by the group coordinated by Guillermo Velasco have been published in some of the most important journals in the field of cancer research (for example Cancer Cell, Cancer Research, Journal of Clinical Investigation, Cell Death and Differentiation

or Nature Reviews Cancer) have generated three patents and have laid the groundwork for the development of a clinical trial (based on the combined administration of the drug Sativex in combination with temozolomide to patients with GBM) promoted by the company GW pharma ltd: (NCT01812616)
Likewise, the results of the group have led to lay the foundations of another clinical trial in which the drug Crizotinib is administered in combination with TMZ and Radiotherapy to patients with GBM (NCT02270034).
Likewise, the Group of Guillermo Velasco is a consolidated group in the area of Oncology at the "Instituto de Investigaciones sanitarias San Carlos" associated with the Hospital Clinico San Carlos. Since year 2019, Guillermo is the leader of Oncology translational clinical Research at Hospital Clínico San Carlos

Part C. RELEVANT MERITS

C.1. Publications (10 selected publications)

1) Martínez-García M, **Velasco G**, Pineda E, Gil-Gil M, Alameda F, Capellades J, Martín-Soberón MC, López-Valero I, Tovar Ambel E, Foro P, Taus A, Arumi M, Hernández-Laín A, Sepúlveda-Sánchez JM
Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial
Cancers 14(10), 2393 (2022) IF: 6,639 (Q1)

2) Orea-Soufi A, Castillo-Lluva S, Salvador-Tormo N, Martín-Cabrera P, Recuero S, Gabicagogeascoa E, Moreno-Valladares M, Mendiburu-Eliçabe M, Blanco-Gómez A, Ramos-Pittol JM, García-Taboada E, Ocaña A, Cimas FJ, Matheu A, Álvarez-López I, **Velasco G***, Lorente M*.
The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer.
Cancers 13(21):5307 (2021). IF (2020): 6,639 (Q1)
*(GV and ML co-senior authors)

3) Maiani, Emiliano; Milletti, Giacomo; Nazio, Francesca; Holdgaard, Sos Gronbaek; Bartkova, Jirina; Rizza, Salvatore; Cianfanelli, Valentina; Lorente, Mar; Simoneschi, Daniele; Di Marco, Miriam; D'Acunzo, Pasquale; Di Leo, Luca; Rasmussen, Rikke; Montagna, Costanza; Raciti, Marilena; De Stefanis, Cristiano; Gabicagogeascoa, Estibaliz; Rona, Gergely; Salvador, Nelida; Pupo, Emanuela; Merchut-Maya, Joanna Maria; Daniel, Colin J.; Carinci, Marianna; Cesarini, Valeriana; O'sullivan, Alfie; Jeong, Yeon-Tae; Bordi, Matteo; Russo, Francesco; Campello, Silvia; Gallo, Angela; Filomeni, Giuseppe; Lanzetti, Letizia; Sears, Rosalie C.; Hamerlik, Petra; Bartolazzi, Armando; Hynds, Robert E.; Pearce, David R.; Swanton, Charles; Pagano, Michele; Velasco, Guillermo; Papaleo, Elena; De Zio, Daniela; Maya-Mendoza, Apolinar; Locatelli, Franco; Bartek, Jiri; Cecconi, Francesco
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity.
Nature 2021 592, 799–803. DOI: 10.1038/s41586-021-03422-5. IF: 42,779; Posición GV: 41/47

4) López-Valero I, Dávila D, González-Martínez J, Salvador-Tormo, N, Lorente, M, Saiz-Ladera, C; Torres S, Gabicagogeascoa E, Hernández-Tiedra S, García-Taboada E, Mendiburu-Eliçabe M, Rodríguez-Fornés F, Sánchez-Domínguez R, Segovia JC, Sánchez-Gómez P, Matheu A, Sepúlveda J, **Velasco G**
Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells
Theranostics 10, 5120-5136 (2020) IF (2020): 11,556 (D1)

5) López-Valero I, Saiz-Ladera C, Torres S, Hernández-Tiedra S, García-Taboada E, Rodríguez-Fornés F, Barba M, Dávila D, Salvador-Tormo N, Guzmán M, Sepúlveda JM, Sánchez-Gómez P, Lorente M, **Velasco G**

Targeting Glioma Initiating Cells with a combined therapy of cannabinoids and temozolomide
Biochem. Pharmacol. 157, 266-274 (2018) IF (2018): 4,825 (D1)

6) Hernández-Tiedra S, Fabriàs G, Dávila D, Salanueva ÍJ, Casas J, Montes LR, Antón Z, García-Taboada E, Salazar-Roa M, Lorente M, Nylandsted J, Armstrong J, López-Valero I, McKee CS, Serrano-Puebla A, García-López R, González-Martínez J, Abad JL, Hanada K, Boya P, Goñi F, Guzmán M, Lovat P, Jäättelä M, Alonso A, **Velasco G**.
Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization
Autophagy. 12 2213-2229 (2016) IF (2016): 8.593 (Q1)

7) Velasco, G*, Sánchez, C & Guzmán, M "Towards the use of cannabinoids as anti-tumour agents"
Nat Rev Cancer 12, 436-44. (2012) IF (2012): 35.0 (D1)
*GV (Corresponding author)

8) Lorente, M., Torres, S., Salazar, M., Carracedo, A., Hernández-Tiedra, S., Rodríguez-Fornés, F., García-Taboada, E., Meléndez, B., Mollejo, M., Campos-Martín, Y., Lakatosh, SA, Barcia, J., Guzmán, M. & **Velasco, G.** *Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action*
Cell Death Differ **18**:959-73 (2011) IF (2011): 8.849 (D1)

9) Salazar, M., Carracedo, A., Salanueva, I.J. Hernández, S., Lorente, M., Egia, A, Vázquez, P., Blázquez, C., Torres, S., García, S, Nowak, J., Fimia, G.M., Piacentini, M., Cecconi, F., Pandolfi, P.P., González-Feria, L., Iovanna, J.L., Guzmán, M., Boya, P. & **Velasco, G.** Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.
J. Clin. Invest. **119**:1359-1372 (2009) IF (2009): 15.387 (D1)

10) Carracedo, A., Lorente, M., Egia, A., Blázquez, C., García, S., Giroux, V., Malicet, C., Villuendas, R., Gironella, M., González-Feria, L., Piris, M.A., Iovanna, J.L., Guzmán, M., **Velasco, G.** *The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells*
Cancer Cell **9**, 301-312 (2006) IF (2006): 24.077 (D1)

C.2. Research projects and grants

Guillermo Velasco has obtained financial support as principal investigator from regional, national or international calls on a continued manner for the last 18 years

Selected more recent projects:

TÍTLE OF THE PROJECT: Hacia el Desarrollo de terapias individualizadas en gliomas basadas en el bloqueo del eje MDK/ALK y la utilización de cannabinoidesFUNDING INSTITUTION: MINECO/ISC III (PI21/00343)
DURATION FROM: 01/01/2021 TO: 31/12/2023
PRINCIPAL INVESTIGATOR: Guillermo Velasco; FUNDING: 268.620,00 €

TÍTLE OF THE PROJECT: Tribbles Research and Innovation Network (TRAIN – GA 721532)
FUNDING INSTITUTION: European Union (H2020), Marie Skłodowska-Curie Innovative Training Network (ITN)
DURATION FROM: 01/09/2016 TO: 31/10/2020
PRINCIPAL INVESTIGATOR: Endre Kiss Toth (Project coordinator)/ Guillermo Velasco (IP IdISSC-UCM group); FUNDING: 3.368.370 € / 430.946 € IdISSC-UCM

TÍTLE OF THE PROJECT: Mechanism of autophagy-mediated cancer cell death and participation of autophagy associated genes in the control of tumorigenesis.
FUNDING INSTITUTION: MINECO/ISC III (PI18/00442)

DURATION FROM: 01/01/2019 TO: 31/12/2021
PRINCIPAL INVESTIGATOR: Guillermo Velasco; FUNDING: 153.670 €

TÍTLE OF THE PROJECT: Role of Autophagy in cancer; Mechanism of autophagy-mediated cancer cell death and participation of autophagy associated genes in the control of tumorigenesis.
FUNDING INSTITUTION: MINECO/ISC III (PI15/00339)
DURATION FROM: 01/01/2016 TO: 31/12/2018
PRINCIPAL INVESTIGATOR: Guillermo Velasco; FUNDING: 244.420 €

TÍTLE OF THE PROJECT: Role of ORMDLs - a novel family of sphingolipid biosynthesis regulators - in cannabinoid anticancer action (15/C/2013)
FUNDING INSTITUTION: FUNDACIÓN TELEMARATÓ
DURATION FROM: 07/05/2014 TO: 31/12/2017
PRINCIPAL INVESTIGATORS: Rubén Vicente (Subproject "Universidad Pompeu Fabra") and Guillermo Velasco (Subproject IDISSC-UCM)
FUNDING: 300.000 € (150.000 € Subproject IDISSC-UCM)

C.3. Most relevant contracts with Pharmaceutical companies

TÍTLE OF THE PROJECT: Pre-clinical assessment of efficacy of midkine neutralizing antibodies in combination with cannabinoids and/or TMZ in glioma models in vivo
FUNDING INSTITUTION: Cellmid DURATION: 2015-2017
PRINCIPAL INVESTIGATOR: Guillermo Velasco Díez
FUNDING: 31.696 €

TÍTLE OF THE PROJECT: GW cannabinoids as antitumoral agents
FUNDING INSTITUTION: GW Pharmaceuticals DURATION FROM: 2014 TO: 2016
PRINCIPAL INVESTIGATOR: Guillermo Velasco
FUNDING: 120.000 €

C.4. Patents

TITLE: Antitumoral effects of cannabinoids combinations
AUTHORS: Guillermo Velasco, Manuel Guzmán, Mar Lorente, Sofía Torres y Fátima Rodríguez
PROPRIETARY: GW Pharmaceuticals

TITLE: Cannabinoids in combination with non-cannabinoids chemotherapeutic agents
AUTHORS: Guillermo Velasco, Manuel Guzmán, Mar Lorente y Sofía Torres
PROPRIETARY: GW Pharmaceuticals

TITLE: Phytocannabinoids in the treatment of cancer
AUTHORS: Daniela Parolaro, et al. (G Velasco as one of the inventors)
PROPRIETARY: Otsuka

C5. Member of editorial committees: Academic Editor of Plos One from 2012, Academic editor of Caners from 2019

C6. Project/grant evaluation:
- Member of the AES panel of project evaluation year 2022.
- Member of the AEI cancer panel for FIS 2020 projects (April-June 2020)
- Member of the International cooperation panel from the Flemish Research Council (FWO) from 2010 to 2019
- Frequent reviewer for ANEP (since 2010) and for several regional, national and international agencies as well as for different private Foundations